Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ASRS, ESGCT and Several Investor and Industry Meetings in October

54th Annual Scientific Meeting of the Retina Society, Chicago (IL), USA

Advanced Therapies Connect, online event

GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

2nd Annual Gene Therapy for ophthalmic Disorders, digital event

5th Annual Cell & Gene Therapy World Asia, virtual

Clinical Trials in Rare Diseases Conference 2021, Europe and USA, virtual conference

GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects before LUMEVOQ® treatment in Phase III Trials

Ophthalmology Futures Forums – Euro Retina Virtual Forum, September 8, 2021

UK MHRA grants GenSight Biologics’ LUMEVOQ® ophthalmic gene therapy Promising Innovative Medicine designation